Interprofessional Perspectives on Safety Management With Targeted Therapy for B-cell Malignancies

Interprofessional Perspectives on Safety Management With Targeted Therapy for B-cell Malignancies is organized by Medical Learning Institute, Inc. (MLI), PVI, PeerView Institute for Medical Education.,,Accredited Activity Release Date: October 4, 2021,Accredited Activity Expiration Date: October 3, 2023,,Activity Description:,In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.,,Educational Objectives:,Upon completion of this accredited CE activity, participants should be better able to:,• Cite current evidence and guidelines supporting a treatment role for targeted agents, including BTK and BCL-2 inhibitors, in the management of B-cell malignancies,• Identify the unique spectrum of adverse events associated with the use of targeted agents in B-cell malignancies, including hypertension, bleeding, cardiac events, TLS, neutropenia, fatigue, and others,• Develop team-based management strategies to address the emergence of adverse events in patients with B-cell malignancies receiving therapy with novel agents,• Utilize team-based educational and counseling strategies detailing therapeutic and safety expectations for patients with MCL, CLL, or other B-cell malignancies